A Shingles Vaccine That Protects Your Heart? Oxford Says Maybe

Men saw a 12% reduction in stroke risk specifically. And in absolute terms, this translated to roughly 1% fewer cardiovascular events after seven years; a number that sounds small until you remember we're talking about a vaccine given to millions of older adults. At population scale, even a 1% absolute reduction could mean thousands of avoided heart attacks and strokes.

Not Just Hearts: The Dementia Connection

This isn't the first time Shingrix has shown up where nobody expected it. A growing pile of studies suggests the vaccine may also lower dementia risk.

A 2025 Stanford-led analysis reported about a 20% lower risk of dementia over seven years in Zostavax vaccinated individuals. A 2026 study in Nature Communications found that two doses of Shingrix were associated with a hazard ratio of 0.68 for dementia, meaning roughly a 32% lower risk compared to unvaccinated peers. Multiple other analyses, including work published in Nature Medicine, have echoed similar findings.

The dementia signal is actually more consistent and better studied than the cardiovascular one. Scientists suspect this might relate to Shingrix's powerful adjuvant (the immune-boosting ingredient called AS01B), which could be triggering broader protective immune responses beyond just fighting the varicella-zoster virus.

Pleiotropic Effects: When Vaccines Moonlight

There's a term for this in biology: pleiotropic effects, which just means one thing influencing multiple, seemingly unrelated outcomes. It's like hiring a guitarist who also turns out to be a great accountant.

Shingrix isn't alone in this. The flu vaccine has the strongest evidence for cardiovascular side benefits; a 2024 meta-analysis showed about a 36% reduction in major cardiovascular events in high-risk patients. Pneumococcal vaccines may protect the heart by preventing lung infections that trigger cardiac complications. And COVID-19 vaccines have also shown signals of broader cardioprotective associations in some populations.

Scientists have a few theories for why this happens. Vaccines may reduce systemic inflammation, stabilize arterial plaques, or create something called "trained immunity" where the immune system recalibrates in ways that benefit multiple organ systems. None of these mechanisms are proven yet. But the pattern keeps showing up across different vaccines and different study designs, which makes it harder to dismiss.

The Giant Caveat (Read This Part)

Before anyone starts prescribing Shingrix as a heart medication, let's pump the brakes.

This is still observational evidence. The natural experiment design is stronger than a typical retrospective study, but it's not a randomized controlled trial. There's always the possibility of residual confounding, which means some hidden variable (maybe Shingrix recipients were slightly healthier to begin with, or visited doctors more frequently) could explain part of the difference.

The Oxford investigators themselves said a randomized clinical trial is needed to prove the cardiovascular benefit is real. Independent experts agreed: the data are intriguing, not conclusive. No guideline change is warranted yet. The practical takeaway for clinicians right now is to view any heart benefit as a "nice potential bonus," not a reason to vaccinate.

Reportedly, a nationwide pragmatic randomized clinical trial is being planned to test whether the cardiovascular effect is causal. That trial will be the real verdict.

What This Means for GSK's Cash Cow

Shingrix is already a blockbuster by any measure. In the first half of 2026 alone, it pulled in roughly £1.91 billion in sales. Full-year 2025 revenue hit £3.6 billion, up 8% year over year.

And there's room to grow. If a randomized trial confirms cardiovascular (or dementia) benefits, the health-economic argument for funding shingles vaccination gets dramatically stronger. Governments and insurers that currently see Shingrix as a "nice to have" might start viewing it as essential preventive care for aging populations.

That's the real commercial prize here: not a new indication on the label, but a fundamentally different conversation about the value of the vaccine.

The Bottom Line

A shingles vaccine might protect your heart. It might protect your brain. And nobody designed it to do either of those things. The evidence is building, but it's not bulletproof yet; we need a proper randomized trial to separate correlation from causation.

Still, if you're over 60 and you haven't gotten your shingles vaccine, the list of reasons to roll up your sleeve just got a little longer. Even the skeptics agree: there's no downside to preventing shingles while the cardiovascular question gets sorted out.

Sometimes the best discoveries are the ones you weren't looking for.

One Shot to Rewrite Your Cholesterol Forever

CRISPR Therapeutics just showed that a single IV infusion can slash cholesterol and triglycerides for at least a year by permanently editing a gene in liver cells. The one-year Phase 1a data for CTX310 are stunning, but the jump from 15 patients to the real world is where things get interesting.